Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.56 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.49 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812631 | 0.87 | EPHX2 (0.44) | EPHX2CHEK2KIF11PARP1MTOR | |
| SCHEMBL2819439 | 0.84 | IDH1 (0.49) | EPHX2P2RY14CHEK2KIF11 | |
| SCHEMBL2816965 | 0.82 | EPHX2 (0.53) | EPHX2P2RY14NR1H4MTORCA12 | |
| SCHEMBL7877746 | 0.77 | EPHX2 (0.90) | EPHX2NR1H4MTORCA12CA1 | |
| SCHEMBL2814469 | 0.75 | EPHX2 (0.48) | EPHX2KIF11MTORCA12CA1 | |
| SCHEMBL2812619 | 0.75 | KCNMA1 (0.52) | CHEK2MAPT | |
| SCHEMBL2814672 | 0.74 | HPSE (0.52) | CHEK2KIF11PARP1CA2MAPT | |
| SCHEMBL2816862 | 0.74 | EPHX2 (0.51) | EPHX2KIF11PARP1MTORCA12 | |
| SCHEMBL2812870 | 0.73 | EPHX2 (0.43) | EPHX2MTOR | |
| SCHEMBL2819274 | 0.73 | EPHX2 (0.43) | EPHX2MTORCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-30 | — | — | US | claimed |
| US-8362057-B2 | Insulin resistance; atherosclerosis; cardiovascular disorders; metabolism disorders | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-1910310-B1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20080207720-A1 | Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same | MERCK PATENT GESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1910310-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007014619-A1 | NOVELIMIDAZOLECARBOXAMIDE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207720-A1 | Novel Imidazolecarboxamide Derivatives as Fructose-1,6-Bisphosphatase Inhibitors, and Pharmaceutical Compositions Comprising Same | FBP1, INSR, GPR119 | EPHX2 3561/4885P2RY14 657/4885DGAT1 1091/4885 |
| US-20100249132-A1 | IMIDAZOLE DERIVATIVES | SDHA, SDHB, TPD52L2 | EPHX2 2238/4885P2RY14 4611/4885DGAT1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.